Sudarshan Pharma Industries Ltd IPO Latest & Current News
Get Real-Time Updates on stock market trends and news
Get updates on stock market, Stock related news, Algo Trading, learn profitable strategies.
Join WhatsApp ChannelSudarshan Pharma Industries Ltd IPO
March 09, 2023 - March 14, 2023
Closed
Apply with Angel One
Apply with Zerodha
Pre-Apply with Upstox
Sudarshan Pharma Industries Ltd IPO Details
Issue Open | 09 March 2023 |
Issue Close | 14 March 2023 |
IPO Price | ₹71 to 73 per equity share |
Face Value | ₹10 per equity share |
IPO Size | ₹50.10 Cr. |
Listing At | BSE SME |
IPO Lot Size | 1600 Shares |
Frequently Asked Question
Pre-issue shareholding of the Sudarshan Pharma Industries Ltd IPO promoter is 80.28%.
Closing date of Sudarshan Pharma Industries Ltd IPO is March 14, 2023.
Opening date of Sudarshan Pharma Industries Ltd IPO is March 09, 2023.
Post-issue shareholding of the Sudarshan Pharma Industries Ltd IPO promoter is [.]%.
IPO application is an online process by using UPI or ASBA as a payment method. ASBA IPO application is already available in the net banking of your respective bank account and the UPI application is offered by your Stockbroker, you can invest in SVS Limited IPO using any neatest method at your convenience.
If allotted, you will receive Sudarshan Pharma Industries Ltd IPO shares in your Demat account on March 21, 2023.
Minimum and maximum order quantity is 1 lot only.
Lot size of the Sudarshan Pharma Industries Ltd IPO is 1600 shares.
Per share price of Sudarshan Pharma Industries Ltd IPO is ₹71 to ₹73 per share.
Sudarshan Pharma Industries Ltd IPO Shares will get listed at BSE SME.
Face value of Sudarshan Pharma Industries Ltd IPO is ₹10 per share.
If you do not get the allotment of Sudarshan Pharma Industries Ltd IPO shares, your IPO application amount will be released or credited back to your bank account via which you applied for this IPO.
Sudarshan Pharma Industries Ltd IPO shares will get listed on March 22, 2023.
Comments for Sudarshan Pharma Industries Ltd IPO Latest & Current News
0 comments